Literature DB >> 11474010

Serosubtypes and PorA types of Neisseria meningitidis serogroup B isolated in Brazil during 1997--1998: overview and implications for vaccine development.

C T Sacchi1, A P Lemos, T Popovic, J C De Morais, A M Whitney, C E Melles, L M Brondi, L M Monteiro, M V Paiva, C A Solari, L W Mayer.   

Abstract

Meningococcal disease caused by N. meningitidis serogroup B (MenB) has been endemic in Brazil since 1997. In this study, we determined the prevalence of serosubtypes of MenB isolated in 10 Brazilian states and the Federal District during 1997 and 1998 and investigated the extent of PorA VR sequence variation among the most prevalent serosubtypes to evaluate the possible use of an outer membrane vesicle (OMV)-, PorA-based vaccine to prevent meningococcal disease in Brazil. During this period, a total of 8,932 cases of meningococcal disease were reported. Only 42% (n = 3,751) of the reported cases were laboratory confirmed, and about 60% (n = 2,255) of those were identified as MenB. Among 1,297 MenB strains selected for this study, the most prevalent serosubtypes were P1.19,15 (66%), P1.7,1 (11%), and P1.7,16 (4%). PorA VR typing showed that 91% of the P1.19,15 strains analyzed had VR1 and VR2 sequences identical to those of the prototype strain. No sequence variation was detected among the 40 strains representing all isolated MenB P1.7,16 strains in the three southern states, where this serosubtype accounts for 75% of the serosubtypes identified. Similarly, all P1.7,1 strains were identified by PorA typing as P1.7-1,1. Although further improvements in the reporting of cases and collection of strains in Brazil are needed, our data suggest that a trivalent OMV-based vaccine prepared with PorA types P1.19,15, P1.7-1,1, and P1.7,16 may be appropriate to control serogroup B meningococcal disease in most of the Brazilian states.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11474010      PMCID: PMC88257          DOI: 10.1128/JCM.39.8.2897-2903.2001

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  42 in total

1.  Diversity and prevalence of PorA types in Neisseria meningitidis serogroup B in the United States, 1992-1998.

Authors:  C T Sacchi; A M Whitney; T Popovic; D S Beall; M W Reeves; B D Plikaytis; N E Rosenstein; B A Perkins; M L Tondella; L W Mayer
Journal:  J Infect Dis       Date:  2000-09-08       Impact factor: 5.226

2.  Immunogenicity and safety of a hexavalent meningococcal outer-membrane-vesicle vaccine in children of 2-3 and 7-8 years of age.

Authors:  E D de Kleijn; R de Groot; J Labadie; A B Lafeber; G van den Dobbelsteen; L van Alphen; H van Dijken; B Kuipers; G W van Omme; M Wala; R Juttmann; H C Rümke
Journal:  Vaccine       Date:  2000-02-14       Impact factor: 3.641

3.  Immunologic response of man to group B meningococcal polysaccharide vaccines.

Authors:  F A Wyle; M S Artenstein; B L Brandt; E C Tramont; D L Kasper; P L Altieri; S L Berman; J P Lowenthal
Journal:  J Infect Dis       Date:  1972-11       Impact factor: 5.226

4.  Safety and immunogenicity of group Y and group W135 meningococcal capsular polysaccharide vaccines in adults.

Authors:  J M Griffiss; B L Brandt; P L Altieri; G B Pier; S L Berman
Journal:  Infect Immun       Date:  1981-12       Impact factor: 3.441

5.  Five structural classes of major outer membrane proteins in Neisseria meningitidis.

Authors:  C M Tsai; C E Frasch; L F Mocca
Journal:  J Bacteriol       Date:  1981-04       Impact factor: 3.490

6.  Epidemic disease due to serogroup C Neisseria meningitidis in Saõ Paulo, Brazil.

Authors:  J Souza de Morais; R S Munford; J B Risi; E Antezana; R A Feldman
Journal:  J Infect Dis       Date:  1974-05       Impact factor: 5.226

7.  Distribution of Neisseria meningitidis serogroup B serosubtypes and serotypes circulating in the United States. The Active Bacterial Core Surveillance Team.

Authors:  M L Tondella; T Popovic; N E Rosenstein; D B Lake; G M Carlone; L W Mayer; B A Perkins
Journal:  J Clin Microbiol       Date:  2000-09       Impact factor: 5.948

8.  Immunogenicity and reactogenicity in UK infants of a novel meningococcal vesicle vaccine containing multiple class 1 (PorA) outer membrane proteins.

Authors:  K Cartwright; R Morris; H Rümke; A Fox; R Borrow; N Begg; P Richmond; J Poolman
Journal:  Vaccine       Date:  1999-06-04       Impact factor: 3.641

9.  Evaluation of two tetravalent (ACYW135) meningococcal vaccines in infants and small children: a clinical study comparing immunogenicity of O-acetyl-negative and O-acetyl-positive group C polysaccharides.

Authors:  H Peltola; A Safary; H Käyhty; V Karanko; F E André
Journal:  Pediatrics       Date:  1985-07       Impact factor: 7.124

Review 10.  Meningococcal disease: still with us.

Authors:  H Peltola
Journal:  Rev Infect Dis       Date:  1983 Jan-Feb
View more
  5 in total

1.  Hospital-based surveillance of meningococcal meningitis in Salvador, Brazil.

Authors:  Soraia M Cordeiro; Alan B Neves; Cássio T Ribeiro; Maya L Petersen; Edilane L Gouveia; Guilherme S Ribeiro; Tatiana S Lôbo; Joice N Reis; Kátia M Salgado; Mitermayer G Reis; Albert I Ko
Journal:  Trans R Soc Trop Med Hyg       Date:  2007-08-06       Impact factor: 2.184

2.  Clonal analysis of Neisseria meningitidis serogroup B strains in South Africa, 2002 to 2006: emergence of new clone ST-4240/6688.

Authors:  Chivonne Moodley; Mignon du Plessis; Kedibone Ndlangisa; Linda de Gouveia; Keith P Klugman; Anne von Gottberg
Journal:  J Clin Microbiol       Date:  2012-09-12       Impact factor: 5.948

3.  Invasive meningococcal disease in Quebec, Canada, due to an emerging clone of ST-269 serogroup B meningococci with serotype antigen 17 and serosubtype antigen P1.19 (B:17:P1.19).

Authors:  Dennis K S Law; Manon Lorange; Louise Ringuette; Réjean Dion; Michel Giguère; Averil M Henderson; Jan Stoltz; Wendell D Zollinger; Philippe De Wals; Raymond S W Tsang
Journal:  J Clin Microbiol       Date:  2006-08       Impact factor: 5.948

4.  Molecular epidemiology of Neisseria meningitidis serogroup B in Brazil.

Authors:  Ivano de Filippis; Ana Paula S de Lemos; Jessica B Hostetler; Kurt Wollenberg; Claudio T Sacchi; Julie C Dunning Hotopp; Lee H Harrison; Margaret C Bash; D Rebecca Prevots
Journal:  PLoS One       Date:  2012-03-14       Impact factor: 3.240

5.  Neisseria meningitidis serogroup W135 sequence type 11, Anhui Province, China, 2011-2013.

Authors:  Shoukui Hu; Wenyan Zhang; Furong Li; Zhongwang Hu; Erjian Ma; Tianli Zheng; Yingying Zhao; Wei Li; Haijian Zhou; Zhujun Shao; Jianguo Xu
Journal:  Emerg Infect Dis       Date:  2014-07       Impact factor: 6.883

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.